Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 1
2010 7
2011 10
2012 16
2013 19
2014 13
2015 7
2016 8
2017 6
2018 11
2019 19
2020 24
2021 26
2022 11
2023 7
2024 13
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

155 results

Results by year

Filters applied: . Clear all
Page 1
Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-IgG-Associated Disease and Neuromyelitis Optica Spectrum Disorders.
Ringelstein M, Ayzenberg I, Lindenblatt G, Fischer K, Gahlen A, Novi G, Hayward-Könnecke H, Schippling S, Rommer PS, Kornek B, Zrzavy T, Biotti D, Ciron J, Audoin B, Berthele A, Giglhuber K, Zephir H, Kümpfel T, Berger R, Röther J, Häußler V, Stellmann JP, Whittam D, Jacob A, Kraemer M, Gueguen A, Deschamps R, Bayas A, Hümmert MW, Trebst C, Haarmann A, Jarius S, Wildemann B, Grothe M, Siebert N, Ruprecht K, Paul F, Collongues N, Marignier R, Levy M, Karenfort M, Deppe M, Albrecht P, Hellwig K, Gold R, Hartung HP, Meuth SG, Kleiter I, Aktas O; Neuromyelitis Optica Study Group (NEMOS). Ringelstein M, et al. Among authors: collongues n. Neurol Neuroimmunol Neuroinflamm. 2021 Nov 16;9(1):e1100. doi: 10.1212/NXI.0000000000001100. Print 2022 Jan. Neurol Neuroimmunol Neuroinflamm. 2021. PMID: 34785575 Free PMC article.
Clinical Features and Risk of Relapse in Children and Adults with Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.
Cobo-Calvo A, Ruiz A, Rollot F, Arrambide G, Deschamps R, Maillart E, Papeix C, Audoin B, Lépine AF, Maurey H, Zephir H, Biotti D, Ciron J, Durand-Dubief F, Collongues N, Ayrignac X, Labauge P, Meyer P, Thouvenot E, Bourre B, Montcuquet A, Cohen M, Horello P, Tintoré M, De Seze J, Vukusic S, Deiva K, Marignier R; NOMADMUS, KidBioSEP, and OFSEP study groups. Cobo-Calvo A, et al. Among authors: collongues n. Ann Neurol. 2021 Jan;89(1):30-41. doi: 10.1002/ana.25909. Epub 2020 Oct 15. Ann Neurol. 2021. PMID: 32959427
[Love and neurology].
Collongues N, Cretin B, de Seze J, Blanc F. Collongues N, et al. Rev Neurol (Paris). 2011 Feb;167(2):105-13. doi: 10.1016/j.neurol.2010.03.023. Epub 2010 May 13. Rev Neurol (Paris). 2011. PMID: 20466399 Review. French.
[Sepsis associated encephalopathy].
Cretin B, Collongues N, Philippi N, Blanc F. Cretin B, et al. Among authors: collongues n. Rev Neurol (Paris). 2011 Mar;167(3):195-204. doi: 10.1016/j.neurol.2010.07.019. Rev Neurol (Paris). 2011. PMID: 20888023 Review. French.
High-Efficacy Therapy Discontinuation vs Continuation in Patients 50 Years and Older With Nonactive MS.
Jouvenot G, Courbon G, Lefort M, Rollot F, Casey R, Le Page E, Michel L, Edan G, de Seze J, Kremer L, Bigaut K, Vukusic S, Mathey G, Ciron J, Ruet A, Maillart E, Labauge P, Zephir H, Papeix C, Defer G, Lebrun-Frenay C, Moreau T, Laplaud DA, Berger E, Stankoff B, Clavelou P, Thouvenot E, Heinzlef O, Pelletier J, Al-Khedr A, Casez O, Bourre B, Cabre P, Wahab A, Magy L, Camdessanché JP, Doghri I, Moulin S, Ben-Nasr H, Labeyrie C, Hankiewicz K, Neau JP, Pottier C, Nifle C, Collongues N, Kerbrat A; OFSEP Investigators. Jouvenot G, et al. Among authors: collongues n. JAMA Neurol. 2024 May 1;81(5):490-498. doi: 10.1001/jamaneurol.2024.0395. JAMA Neurol. 2024. PMID: 38526462
Serum Biomarker Profiles Discriminate AQP4 Seropositive and Double Seronegative Neuromyelitis Optica Spectrum Disorder.
Carta S, Dinoto A, Capobianco M, Valentino P, Montarolo F, Sala A, Reindl M, Lo Re M, Chiodega V, Branger P, Audoin B, Aboab J, Papeix C, Collongues N, Kerschen P, Zephir H, Créange A, Bourre B, Schanda K, Flanagan EP, Redenbaugh V, Villacieros-Álvarez J, Arrambide G, Cobo-Calvo A, Ferrari S, Marignier R, Mariotto S. Carta S, et al. Among authors: collongues n. Neurol Neuroimmunol Neuroinflamm. 2024 Jan;11(1):e200188. doi: 10.1212/NXI.0000000000200188. Epub 2023 Dec 22. Neurol Neuroimmunol Neuroinflamm. 2024. PMID: 38134369 Free PMC article.
Rituximab De-escalation in Patients With Neuromyelitis Optica Spectrum Disorder.
Demuth S, Collongues N, Audoin B, Ayrignac X, Bourre B, Ciron J, Cohen M, Deschamps R, Durand-Dubief F, Maillart E, Papeix C, Ruet A, Zephir H, Marignier R, De Seze J; NOMADMUS Study Group. Demuth S, et al. Among authors: collongues n. Neurology. 2023 Jul 25;101(4):e438-e450. doi: 10.1212/WNL.0000000000207443. Epub 2023 Jun 8. Neurology. 2023. PMID: 37290967 Free PMC article.
Advocating for rituximab as first-line treatment for NMOSD-AQP4 patients in France: Cost and efficacy considerations.
Deschamps R, Papeix C, Ayrignac X, Bourre B, Ciron J, Cohen M, Collongues N, Deiva K, Durand Dubief F, Laplaud DA, Maillart E, Michel L, Pique J, Ruet A, Thouvenot E, Zéphir H, Marignier R, Audoin B. Deschamps R, et al. Among authors: collongues n. Rev Neurol (Paris). 2024 Oct;180(8):711-714. doi: 10.1016/j.neurol.2024.06.003. Epub 2024 Jul 4. Rev Neurol (Paris). 2024. PMID: 38969609 No abstract available.
155 results